Acquiring Company
XOMA Royalty Corporation
Acquired Company
LAVA Therapeutics
Berkeley
UtrechtBiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics N.V., acquiring all outstanding common shares at a price of $1.04 per share in cash. LAVA shareholders will also receive contingent value rights representing future payments related to LAVA's partnered assets. This acquisition is expected to enhance XOMA's product portfolio and drive significant value creation.
Quick answer
XOMA Royalty Corporation is acquiring LAVA Therapeutics, announced November 21, 2025. XOMA Royalty Corporation is based in Berkeley, California, United States.
- How much did XOMA Royalty Corporation pay for LAVA Therapeutics?
- The deal value was not disclosed.
- What does XOMA Royalty Corporation do?
- XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.
- Where are XOMA Royalty Corporation and LAVA Therapeutics based?
- XOMA Royalty Corporation is based in Berkeley, California, United States. LAVA Therapeutics is based in Utrecht, Utrecht, Netherlands.
- Who are the decision-makers at XOMA Royalty Corporation?
- Fundz holds 3 contacts at XOMA Royalty Corporation. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Pfizer completes $43 billion acquisition of Seagen, $43B (January 4, 2026)
- Day One to acquire Mersana for $130 million, $130M (November 30, 2025)
- BioNTech completes acquisition of CureVac (December 20, 2025)
- Pfizer to acquire Metsera for $10 billion, $10B (November 15, 2025)
- Pfizer increases bid for Metsera in bidding war (November 8, 2025)
- Pfizer secures clearance for Metsera acquisition (October 31, 2025)
Who to call at XOMA Royalty Corporation, and when
When XOMA Royalty Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day XOMA Royalty Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at XOMA Royalty Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at XOMA Royalty Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment XOMA Royalty Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired LAVA Therapeutics?
LAVA Therapeutics was acquired by XOMA Royalty Corporation, based in Berkeley. The deal was reported on November 21, 2025. XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty Corporation is privately held and operates in Biotechnology.
When did XOMA Royalty Corporation acquire LAVA Therapeutics?
XOMA Royalty Corporation's acquisition of LAVA Therapeutics was reported on November 21, 2025. XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics N.V., acquiring all outstanding common shares at a price of $1.04 per share in cash. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does LAVA Therapeutics do?
LAVA Therapeutics N.V. is a biopharmaceutical company developing bispecific gamma delta T cell engagers using its Gammabody® platform. It is privately held, operating in Biotechnology, and is based in Utrecht.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.